CYP2A6 and lung carcinoma: Additionally, these genes could be contributing to lung cancer risk directly through altered nitrosamine pharmacology—the CYP2A6 enzyme metabolically activates tobacco specific nitrosamines (TSNA) [2] and the nicotinic receptors are high-affinity binding sites for nitrosamines [3].